Atlas Trials

CIN2

20 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch CIN2

RecordFirmDate
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine (NCT05371353)Shanghai Bovax Biotechnology Co., Ltd.2022-05-14
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years (NCT05027776)Shanghai Bovax Biotechnology Co., Ltd.2021-09-15
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (NCT04895020)Shanghai Bovax Biotechnology Co., Ltd.2021-05-28
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT05372016)Shanghai Bovax Biotechnology Co., Ltd.2020-09-19
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT04425291)Shanghai Bovax Biotechnology Co., Ltd.2020-05-28
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT04422366)Shanghai Bovax Biotechnology Co., Ltd.2020-04-28
Conservative Management of CIN2 Lesions and Biomarkers Evaluation (NCT04687267)Istituto Oncologico Veneto IRCCS2019-04-15
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT03676101)Shanghai Bovax Biotechnology Co., Ltd.2018-10-10
Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age (NCT03177863)Sahlgrenska University Hospital2017-06-12
Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women. (NCT02956031)University of Pretoria2016-12-01
Cervical Cancer Screening With Human Papillomavirus Testing (NCT01881659)International Agency for Research on Cancer2013-05-01

Track CIN2 automatically

Every clearance here is in the API, with alerts when new ones post.